ICT 21
Alternative Names: ICT-21Latest Information Update: 11 Dec 2023
At a glance
- Originator ImCheck Therapeutics
- Class Anti-inflammatories; Monoclonal antibodies
- Mechanism of Action Butyrophilin inhibitors; T lymphocyte inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Autoimmune disorders
Most Recent Events
- 06 Dec 2023 Preclinical trials in Autoimmune disorders in France (Parenteral) prior to December 2023 (ImCheck Therapeutics pipeline, December 2023)
- 03 Jul 2020 ICT 21 is available for licensing as of 03 Jul 2020. https://www.imchecktherapeutics.com/
- 03 Jul 2020 Early research in Autoimmune disorders in France (Parenteral) before July 2020 (ImCheck Therapeutics pipeline, July 2020)